Get the Stockscreener App
66.46
5.29%
3.34
After Hours:
66.11
-0.35
-0.53%
Inhibrx Biosciences Inc stock is traded at $66.46, with a volume of 189.86K.
It is up +5.29% in the last 24 hours and down -17.20% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$63.12
Open:
$63.56
24h Volume:
189.86K
Relative Volume:
0.95
Market Cap:
$970.78M
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-7.3484
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
-3.25%
1M Performance:
-17.20%
6M Performance:
+108.70%
1Y Performance:
+367.37%
1-Day Range:
$63.56
$68.91
1-Week Range:
$59.98
$68.91
52-Week Range:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
66.46 | 922.00M | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Will Inhibrx Biosciences Inc stock recover after earnings2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data (INBX) - Seeking Alpha
Ideas Watch: Is Inhibrx Biosciences Inc stock undervalued right nowEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.6%Here's Why - MarketBeat
Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday - MarketBeat
Behavioral Patterns of INBX and Institutional Flows - Stock Traders Daily
Inhibrx Biosciences Reports 2025 Financial Results - Intellectia AI
Inhibrx Reports Q4 Revenue of $0, Cash Balance at $124.2M - Intellectia AI
Inhibrx Biosciences Reports Q4 Earnings Miss - Intellectia AI
INBX SEC FilingsInhibrx Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones - AD HOC NEWS
Inhibrx Biosciences, Inc. 2025 Annual Report – Clinical Pipeline, Regulatory Progress, and Company Overview - Minichart
Inhibrx Biosciences (NASDAQ:INBX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Inhibrx Biosciences Q4 net loss narrows as expenses fall - TradingView
Inhibrx Biosciences 10-K: $1.3M revenue, EPS $(9.04) - TradingView
[10-K] Inhibrx Biosciences, Inc. Files Annual Report | INBX SEC FilingForm 10-K - Stock Titan
Inhibrx Biosciences (NASDAQ: INBX) details 2025 loss and 2026 trial plans - Stock Titan
Cancer drug filing tops Inhibrx milestones as cash reaches $124.2M - Stock Titan
Stock Analysis: Is Inhibrx Biosciences Inc a turnaround story2026 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
Boothbay Fund Management LLC Boosts Holdings in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Growth Value: What is Inhibrx Biosciences Incs P E ratio telling usQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences Inc expected to post a loss of $2.08 a shareEarnings Preview - TradingView
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd - Defense World
(INBX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Inhibrx Biosciences : ESMO Sarcoma and Rare Cancers Congress 2026 (INBRX-109 in Ewing sarcoma Data Update Oral Presentation) - marketscreener.com
Market Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday - MarketBeat
Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
INBX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight - The Malaysian Reserve
INBX Technical Analysis & ETF Price Forecast - Intellectia AI
INBX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy - The Globe and Mail
Market Leaders: Is Inhibrx Biosciences Inc stock undervalued right nowWeekly Loss Report & Reliable Price Action Trade Plans - baoquankhu1.vn
Chipmakers Recap: Is RNAC vulnerable to short sellersBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Trading Systems Reacting to (INBX) Volatility - Stock Traders Daily
Readystate Asset Management LP Acquires 143,324 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Contrasting Immuneering (NASDAQ:IMRX) and Inhibrx Biosciences (NASDAQ:INBX) - Defense World
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial - MarketBeat
Will Inhibrx Biosciences Inc. be affected by tariffsJuly 2025 Intraday Action & Accurate Intraday Trade Tips - mfd.ru
Merger Talk: Is Inhibrx Biosciences Inc stock a hidden gem2025 Volume Leaders & Weekly Watchlist of Top Performers - baoquankhu1.vn
What is the long term forecast for Inhibrx Biosciences Inc. stockEarnings Overview Summary & Pattern Based Trade Signal System - mfd.ru
Inhibrx Biosciences and Immuneering Compared in Financial Analysis - National Today
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 6.8%Here's What Happened - MarketBeat
Will Inhibrx Biosciences Inc. stock return to pre crisis levels2025 Trade Ideas & Verified Stock Trade Ideas - mfd.ru
Is Inhibrx Biosciences Inc. still a buy after recent gainsDay Trade & Stepwise Entry/Exit Trade Alerts - mfd.ru
Fund Flows: Whats the beta of Inhibrx Biosciences Inc stock2025 Market WrapUp & Reliable Breakout Forecasts - baoquankhu1.vn
Is Inhibrx Biosciences Inc. forming a bullish divergence2025 Sector Review & Daily Growth Stock Tips - mfd.ru
Morgan Stanley discloses 7.9% Inhibrx (INBX) stake in 13G filing - Stock Titan
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):